Gutenberg Open Science: Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer : results of an exploratory case

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-5969

Full metadata record

DC Field	Value	Language
dc.contributor.author	Krajnak, Slavomir	-
dc.contributor.author	Schnatz, C.	-
dc.contributor.author	Almstedt, Katrin	-
dc.contributor.author	Brenner, Walburgis	-
dc.contributor.author	Haertner, F.	-
dc.contributor.author	Heimes, Anne-Sophie	-
dc.contributor.author	Lebrecht, Antje	-
dc.contributor.author	Makris, G.-M.	-
dc.contributor.author	Schwab, Roxana	-
dc.contributor.author	Hasenburg, Annette	-
dc.contributor.author	Schmidt, Marcus	-
dc.contributor.author	Battista, Marco J.	-
dc.date.accessioned	2021-06-04T08:46:39Z	-
dc.date.available	2021-06-04T08:46:39Z	-
dc.date.issued	2020	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/5978	-
dc.description.abstract	PURPOSE There is growing interest in low-dose metronomic chemotherapy (LDMC) in metastatic breast cancer (MBC). In this retrospective case–control analysis, we compared the efficacy of LDMC and conventional chemotherapy (CCT) in MBC. METHODS Each LDMC patient receiving oral cyclophosphamide (CTX) (50 mg daily) and methotrexate (MTX) (2.5 mg every other day) was matched with two controls who received CCT. Age, number of chemotherapy lines and metastatic sites as well as hormone receptor (HR) status were considered as matching criteria. Primary endpoint was disease control rate longer than 24 weeks (DCR). Secondary endpoints were progression-free survival (PFS), duration of response (DoR) and subgroup analyses using the matching criteria. RESULTS 40 cases and 80 controls entered the study. 30.0% patients with LDMC and 22.5% patients with CCT showed DCR (p = 0.380). The median PFS was 12.0 weeks in both groups (p = 0.218) and the median DoR was 31.0 vs. 20.5 weeks (p = 0.383), respectively. Among younger patients, DCR was 40.0% in LDMC vs. 25.0% in the CCT group (p = 0.249). DCR was achieved in 33.3% vs. 26.2% non-heavily pretreated patients (p = 0.568) and in 36.0% vs. 18.0% patients without multiple metastases (p = 0.096), respectively. In the HR-positive group, 30.0% LDMC vs. 28.3% CCT patients showed DCR (p = 1.000). Among triple-negative patients, DCR was achieved in 30.0% LDMC and 5.0% CCT patients (p = 0.095). CONCLUSIONS We demonstrated a similar efficacy of LDMC compared to CCT in the treatment of MBC. Thus, LDMC may be a valuable treatment option in selected MBC patients.	en_GB
dc.language.iso	eng	de
dc.rights	CC BY	*
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/	*
dc.subject.ddc	610 Medizin	de_DE
dc.subject.ddc	610 Medical sciences	en_GB
dc.title	Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer : results of an exploratory case–control study	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-5969	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 04 Medizin	de
jgu.organisation.number	2700	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	Breast cancer research and treatment	de
jgu.journal.volume	182	de
jgu.pages.start	389	de
jgu.pages.end	399	de
jgu.publisher.year	2020	-
jgu.publisher.name	Springer Science + Business Media B.V.	de
jgu.publisher.place	Dordrecht u.a.	de
jgu.publisher.uri	https://doi.org/10.1007/s10549-020-05711-5	de
jgu.publisher.issn	1573-7217	de
jgu.organisation.place	Mainz	-
jgu.subject.ddccode	610	de
jgu.publisher.doi	10.1007/s10549-020-05711-5	-
jgu.organisation.ror	https://ror.org/023b0x485	-
Appears in collections:	JGU-Publikationen

Files in This Item:

	File	Description	Size	Format
	krajnak_s.-low-dose_metro-20210527011422443.pdf		1.19 MB	Adobe PDF	View/Open

Show simple item record